Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

30 Key Patents about Cord Blood (UPSTO)

December 13, 2016 By Cade Hildreth, Founder & President Leave a Comment

A crucial benchmark to track for the cord blood market is the number and type of cord blood related patents that have been issued.

The United States Patent and Trademark Office (USPTO) has a patent analysis tool that offers a “Full Text and Image Database Search.” The database includes information about all American patents, from the first patent issued in 1790 to the most recent issue week.¹ The text of patents issued from January 1976 to the present is fully searchable, including bibliographic data, such as the inventor’s name, the patent’s title, and the assignee’s name; the abstract; the full description of the invention; and the claims.² [Read more…]

Precious Cells Group is First Employer Worldwide to Bank Stem Cells for Employees

December 8, 2016 By Cade Hildreth, Founder & President Leave a Comment

First Ever Employer to Store Lifesaving Stem Cells for Employees

Edinburgh, UK, December 7, 2016 – Precious Cells is offering their employees the ultimate employee benefit unlike anything ever seen before. They will cryogenically store employees’ and their loved ones’ stem cells, for free. This means they can be used in treatment for life threatening conditions today, tomorrow and in the future. [Read more…]

Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies

December 8, 2016 By Cade Hildreth, Founder & President Leave a Comment

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients

New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]

Gamida Cell Presents Positive Data From Phase 1/2 Study of NiCord® as a Curative Treatment for Sickle Cell Disease at ASH 2016

December 6, 2016 By Cade Hildreth, Founder & President Leave a Comment

Sickle cell disease patients treated with NiCord® showed rapid engraftment and were cured of disease symptoms.

Jerusalem, Israel, Tuesday, December 6, 2016 — Gamida Cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, today announced results from its Phase 1/2 study of NiCord® for Sickle Cell Disease (SCD). The data were presented during a poster session at the 58^th American Society of Hematology (ASH) Annual Meeting & Exposition, December 3-5, 2016 in San Diego, CA. [Read more…]

CariCord Partners with Singapore’s CellResearch Corp to Join “Global Cord Registry” & Launch Cord Tissue Storage in U.S.

November 30, 2016 By Cade Hildreth, Founder & President Leave a Comment

Singapore’s CellResearch Corporation has entered into an agreement with CariCord to provide umbilical cord tissue banking services within the United States. CariCord is the private cord blood and tissue banking partner of ClinImmune Labs at the University of Colorado.

As stated in the November 30, 2016, press release:

“CellResearch Corporation Pte Ltd (“CellResearch”), a Singapore-based company that specializes in stem cell technology, through its wholly owned subsidiary, CordLabs Pte Ltd (“CordLabs”), has entered into an agreement with CariCord Inc. (“CariCord”) to provide umbilical cord tissue banking services in the United States. CariCord is the private postnatal cord blood and tissue banking partner of ClinImmune Labs (“ClinImmune”) at the University of Colorado, Anschutz Medical Campus (“UCAMC”).

This agreement extends CellResearch’s on-going collaboration with ClinImmune. The two groups are already working together to obtain US Federal Drug Agency (“US FDA”) approval for Corlicyte™, a drug for the treatment of diabetic wounds. ClinImmune will produce the world’s first Current Good Manufacturing Practices (“cGMP”) cord lining mesenchymal stem cell lines for therapeutic use.”

This license agreement also allows CariCord’s cord tissue clients to join CellResearch’s Global Cord Registry (“GCR”), “a proprietary registry for all clients who have saved cord lining stem cells with licensed partners.” The registry currently has 50,000+ registered clients, making it the largest group of its type in the world.

Cord Blood

First Ever Employer to Store Lifesaving Stem Cells for Employees

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients

Sickle cell disease patients treated with NiCord® showed rapid engraftment and were cured of disease symptoms.

As stated in the November 30, 2016, press release:

To learn more, read the full press release from CellResearch Corporation.